Skip to main content
Erschienen in:

21.07.2017 | Original Article

Evaluation of the safety and efficacy of metoprolol infusion for children and adolescents with hypertensive crises: a retrospective case series

verfasst von: Rola Saqan, Hanan Thiabat

Erschienen in: Pediatric Nephrology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute severe hypertension occurs infrequently in pediatric patients and, consequently, data on the efficacy and safety of most antihypertensive agents, as well as the adverse events associated with these agents, are very limited in this population. In this case series, we evaluated the use of metoprolol infusion in children with hypertensive emergencies.

Methods

The study population comprised children younger than 18 years who had been admitted to the pediatric intensive care unit at King Abdullah University Hospital with blood pressure above the 99th percentile for age, height, and sex and who were symptomatic at the time of presentation. Metoprolol was given as an infusion at a dose of 1–5 mcg/kg/min. The rate of decrease in blood pressure, side effects from the medication, and outcome were assessed.

Results

Thirteen patients ranging in age from 2 months to 16 years were included in this study. The initial mean blood pressure was 23–75 mmHg above the 99th percentile for age, height, and sex. Metoprolol was initiated at a dose of 0.5 mcg/kg/min and titrated according to the target blood pressure to a maximum of 5 mcg/kg/min. Mean blood pressure fell by an average of 12.3, 20.4, and 27.1% at 1, 8, and 24 h, respectively, which is consistent with findings on the use of other intravenous medications reported in published studies. The heart rate did not decrease below the normal range for age. There were no significant side effects of the metoprolol infusion. All patients were discharged home with no neurological sequelae secondary to their hypertension.

Conclusion

An infusion of metoprolol for a hypertensive emergency is a safe and effective treatment for pediatric patients.
Literatur
1.
Zurück zum Zitat Falkner B, Daniels SR (2004) Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Hypertension 44(4):387–388CrossRefPubMed Falkner B, Daniels SR (2004) Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Hypertension 44(4):387–388CrossRefPubMed
2.
Zurück zum Zitat Tuncel M, Ram VC (2003) Hypertensive emergencies. Etiology and management. Am J Cardiovasc Drugs 3:21–31CrossRefPubMed Tuncel M, Ram VC (2003) Hypertensive emergencies. Etiology and management. Am J Cardiovasc Drugs 3:21–31CrossRefPubMed
3.
Zurück zum Zitat Marik PE, Varon J (2007) Hypertensive crises: challenges and management. Chest 131:1949–1962CrossRefPubMed Marik PE, Varon J (2007) Hypertensive crises: challenges and management. Chest 131:1949–1962CrossRefPubMed
5.
6.
Zurück zum Zitat Pancioli AM (2008) Hypertension management in neurologic emergencies. Ann Emerg Med 51:S24–S27CrossRefPubMed Pancioli AM (2008) Hypertension management in neurologic emergencies. Ann Emerg Med 51:S24–S27CrossRefPubMed
7.
Zurück zum Zitat Welch WP, Yang W, Taylor-Zapata P, Flynn JT (2012) Antihypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens (Greenwich) 14:388–395CrossRef Welch WP, Yang W, Taylor-Zapata P, Flynn JT (2012) Antihypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens (Greenwich) 14:388–395CrossRef
8.
Zurück zum Zitat Perez MI, Musini VM (2008) Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 22:596–607CrossRefPubMed Perez MI, Musini VM (2008) Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens 22:596–607CrossRefPubMed
9.
Zurück zum Zitat Flynn J, Bradford M, Harvey E (2014) Intravenous hydralazine in hypertensive pediatric inpatients: does it work? Is it safe? J Am Soc Hypertens 8(4S):e130CrossRef Flynn J, Bradford M, Harvey E (2014) Intravenous hydralazine in hypertensive pediatric inpatients: does it work? Is it safe? J Am Soc Hypertens 8(4S):e130CrossRef
10.
Zurück zum Zitat Flynn JT (2003) Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2:133CrossRefPubMed Flynn JT (2003) Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2:133CrossRefPubMed
11.
Zurück zum Zitat Gouyon JB, Geneste B, Semama DS, Françoise M, Germain JF (1997) Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed 76:F126–F127CrossRefPubMedPubMedCentral Gouyon JB, Geneste B, Semama DS, Françoise M, Germain JF (1997) Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed 76:F126–F127CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38–43CrossRefPubMed Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38–43CrossRefPubMed
13.
Zurück zum Zitat Thomas CA, Moffett BS, Wagner JL, Mott AR, Feig DI (2011) Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 12:28–32CrossRefPubMed Thomas CA, Moffett BS, Wagner JL, Mott AR, Feig DI (2011) Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 12:28–32CrossRefPubMed
14.
Zurück zum Zitat Hammer GB, Lewandowski A, Drover DR, Rosen DA, Cohane C, Anand R, Mitchell J, Reece T, Schulman SR (2015) Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. Pediatr Crit Care Med 16:397–403CrossRefPubMed Hammer GB, Lewandowski A, Drover DR, Rosen DA, Cohane C, Anand R, Mitchell J, Reece T, Schulman SR (2015) Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. Pediatr Crit Care Med 16:397–403CrossRefPubMed
15.
Zurück zum Zitat Tangeman HJ, Patterson JH (2003) Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother 37:701–710CrossRefPubMed Tangeman HJ, Patterson JH (2003) Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother 37:701–710CrossRefPubMed
16.
Zurück zum Zitat Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J, MERIT-HF Study Group (2005) Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149:159–167CrossRefPubMed Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J, MERIT-HF Study Group (2005) Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149:159–167CrossRefPubMed
17.
Zurück zum Zitat Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, Portman RJ, Falkner B, Toprol-XL Pediatric Hypertension Investigators (2007) Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 150:134–139 139.e1 CrossRefPubMed Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, Portman RJ, Falkner B, Toprol-XL Pediatric Hypertension Investigators (2007) Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 150:134–139 139.e1 CrossRefPubMed
18.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252CrossRefPubMed Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206–1252CrossRefPubMed
20.
Zurück zum Zitat Temple ME, Nahata MC (2000) Treatment of pediatric hypertension. Pharmacotherapy 20(2):140–150CrossRefPubMed Temple ME, Nahata MC (2000) Treatment of pediatric hypertension. Pharmacotherapy 20(2):140–150CrossRefPubMed
21.
Zurück zum Zitat Stein DR, Ferguson MA (2016) Evaluation and treatment of hypertensive crises in children. Integr Blood Press Control 9:49–58PubMedPubMedCentral Stein DR, Ferguson MA (2016) Evaluation and treatment of hypertensive crises in children. Integr Blood Press Control 9:49–58PubMedPubMedCentral
22.
Zurück zum Zitat Ostrye J, Hailpern SM, Jones J, Egan B, Chessman K, Shatat IF (2014) The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child. Pediatr Nephrol 29:1403–1409CrossRefPubMed Ostrye J, Hailpern SM, Jones J, Egan B, Chessman K, Shatat IF (2014) The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child. Pediatr Nephrol 29:1403–1409CrossRefPubMed
24.
Zurück zum Zitat Blaszak RT, Savage JA, Ellis EN (2001) The use of short-acting nifedipine in pediatric patients with hypertension. Journal Pediatr 139:34–37CrossRef Blaszak RT, Savage JA, Ellis EN (2001) The use of short-acting nifedipine in pediatric patients with hypertension. Journal Pediatr 139:34–37CrossRef
25.
Zurück zum Zitat Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S (2002) Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 17:35–40CrossRefPubMed Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S (2002) Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 17:35–40CrossRefPubMed
27.
Zurück zum Zitat Shin J, Gonzales M, Pletcher MJ (2013) Risk of emergent bradycardia associated with initiation of immediate- or slow-release metoprolol. Pharmacotherapy 33:1353–1361CrossRefPubMed Shin J, Gonzales M, Pletcher MJ (2013) Risk of emergent bradycardia associated with initiation of immediate- or slow-release metoprolol. Pharmacotherapy 33:1353–1361CrossRefPubMed
28.
Zurück zum Zitat Abraham TA, Hasan FM, Fenster PE, Marcus FI (1981) Effect of intravenous metoprolol on reversible obstructive airways disease. Clin Pharmacol Ther 29:582–587CrossRefPubMed Abraham TA, Hasan FM, Fenster PE, Marcus FI (1981) Effect of intravenous metoprolol on reversible obstructive airways disease. Clin Pharmacol Ther 29:582–587CrossRefPubMed
29.
Zurück zum Zitat Lammers JW, Folgering HT, van Herwaarden CL (1986) Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 8[Suppl 11]:S69–S73PubMed Lammers JW, Folgering HT, van Herwaarden CL (1986) Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 8[Suppl 11]:S69–S73PubMed
30.
Zurück zum Zitat Albouaini K, Andron M, Alahmar A, Egred M (2007) Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2(4):535–540PubMedPubMedCentral Albouaini K, Andron M, Alahmar A, Egred M (2007) Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2(4):535–540PubMedPubMedCentral
31.
Zurück zum Zitat Liesemer K, Mullen N (2009) Hypertensive emergency successfully treated with metoprolol: a case report. Pediatr Emerg Care 25:333–335CrossRefPubMed Liesemer K, Mullen N (2009) Hypertensive emergency successfully treated with metoprolol: a case report. Pediatr Emerg Care 25:333–335CrossRefPubMed
Metadaten
Titel
Evaluation of the safety and efficacy of metoprolol infusion for children and adolescents with hypertensive crises: a retrospective case series
verfasst von
Rola Saqan
Hanan Thiabat
Publikationsdatum
21.07.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 11/2017
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-017-3720-6

Neu im Fachgebiet Pädiatrie

Bildschirmzeit und Myopie: Auf die Dosis kommt es an

  • 20.03.2025
  • Myopie
  • Nachrichten

Mit jeder zusätzlichen Stunde Bildschirmzeit pro Tag steigt das Risiko für Kurzsichtigkeit signifikant an – am stärksten bei Kindern zwischen zwei und sieben Jahren. Aber es könnte eine „sichere“ Nutzungsdauer geben.

Eosinophile Ösophagitis: Doppelte Dosis PPI wirkt besser

Protonenpumpenhemmer führen bei eosinophiler Ösophagitis nur in etwa jedem zweiten Fall zu einer klinischen bzw. histologischen Remission, so das Ergebnis einer Metaanalyse. Verbessern lässt sich die Quote möglicherweise mit einer Dosisverdopplung und der Aufteilung der Tagesdosis.

Mit Probiotika schneller fieberfrei?

Kinder mit fieberhaften Infektionen der oberen Atemwege profitieren möglicherweise von einer unterstützenden Behandlung mit Probiotika. Laut einer Studie aus Mailand steckt dahinter mehr als ein Placeboeffekt.

Hyperpronation beim „Kindermädchen-Ellenbogen“ wohl überlegen

Bei Kindern mit Radiusköpfchen-Subluxation ist die Hyperpronation wohl der klassischen Supinations-Flexionstechnik überlegen, möglicherweise auch im Hinblick auf Schmerzen. Darauf deuten die Ergebnisse einer aktuellen Metaanalyse hin.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.